respect to the correlation of CYP2D6 genotype with assessment of metoprolol pharmacodynamics, surrogate efficacy, and clinical outcome in the context of HF.
Because plasma concentrations of β-blockers mirror the concentrations at the target site and because most beneficial and adverse drug effects are principally dependent on plasma concentration (i.e., mediated by dose-response effects), CYP2D6 genotype-guided metoprolol dose titration may illustrate how HF regimens can be better stratified. 33 Therefore, we conducted a pharmacogenetic substudy in the context of the MERIT-HF trial, to investigate the relationship between CYP2D6 genotype and the clinical pharmacology of metoprolol. Specifically, we wished to assess (i) steady-state concentrations of the active S-enantiomer, (ii) dosing characteristics, (iii) hemodynamic and clinical indicators of β-blockade, and (v) clinical outcomesspecifically, hospitalization and mortality.
RESULTS

Patients, baseline characteristics, and clinical parameters
The patients in this substudy population did not differ in clinical characteristics from those of the main MERIT-HF study. 34, 35 Metoprolol-treated patients were allocated to groups based on genotype; homozygotic extensive metabolizers (EMs; *1*1: 189 patients, 60.4%), heterozygotic intermediate metabolizers (IMs; *1*4: 112 patients, 35 .8%), and homozygotic PMs (*4*4: 12 patients, 3.8%). The allelic prevalence (*4 = 0.22, *1 = 0.78) was consistent with those of previous Northern European studies; 25, 36, 37 frequencies were in Hardy-Weinberg equilibrium (χ 2 = 0.85; P = 0.36). There were no significant differences in baseline characteristics or drug regimens by treatment arm or genotype ( Tables 1 and 2 ).
Effect of CYP2D6 genotype on metoprolol dosing
When stratified by CYP2D6 genotype, there was no difference in starting dose (decided by severity of HF); 41.3% of EMs started on the 12.5-mg half dose, as compared with 43.8% of IMs and 33.3% of PMs (P = 0.76). No differences in dosing profile were observed; mean metoprolol doses at each titration/ follow-up visit did not differ by genotype. A total of 194 participants (62.0%) reached the target dose of 200 mg/day, with no difference in the proportion of each genotype achieving this dose (P = 0.25). At the 90-day follow-up visit, there was no difference in the average dose received between the groups (EMs, IMs, and PMs: 147.4, 146.4, and 175.0 mg/day, respectively; P = 0.29); the three groups had similar interindividual variations in metoprolol dose (SD: 61.7, 61.1, and 50.0 mg/day, respectively ).
Effect of CYP2D6 genotype on metoprolol plasma concentration
The mean, unadjusted 90-day plasma concentration in the metoprolol-treated cohort was 0.33 µmol/l (95% confidence interval (CI): 0.29-0.38), equivalent to 88 ng/ml (95% CI: 78-102). Unadjusted S-metoprolol concentration varied inversely with the number of functional CYP2D6 alleles-a significant allele dose-response effect (Figure 2) . Median S-metoprolol concentrations were 2.1-and 4.6-fold (P < 0.0001) greater in the IM and PM groups, respectively, as compared with the EM group-a trend that remained following dose/weight adjustment (2.1-and 4.5-fold, respectively; P < 0.0001).
Effect of CYP2D6 genotype on hemodynamic measures of β-blockade
Metoprolol therapy was associated with significant reductions in HR (P < 0.0001) and systolic (P < 0.001) and diastolic blood pressure (DBP; P = 0.04). Figure 3 illustrates the decrease in HR with respect to metoprolol dose during dose titration for each CYP2D6 genotype. Comparing EMs vs. IMs, the mean reduction in HR from baseline after 2 weeks was 5.0 vs. 5.8 beats per min (P = 0.15); after 4 weeks, it was 7.9 vs. 10.5 (P = 0.02); after 6, 8, and 12 weeks, it was 9.7 vs. 13.2 (P = 0.01), 13.7 vs. 15.6 (P = 0.04), and 15.9 vs. 16.9 (P = 0.36) beats per min, respectively, on a background of significant pharmacodynamic variability (SD = 5.7-13.9 beats per min). This corresponded to a mean HR reduction from baseline to the 8-week follow-up visit (by which time, patients should have been titrated to the final dose) in the EM, IM, and PM groups of 0.13, 0.17, and 0.19 beats per min per AF, atrial fibrillation; BMI, body mass index; CHF, congestive heart failure; Cr, creatinine; DBP, diastolic blood pressure; EM, extensive metabolizer; HR, heart rate; IM, intermediate metabolizer; K + , potassium; LVEF, left-ventricular ejection fraction; MI, myocardial infarction; Na + , sodium; NYHA, New York Heart Association; PM, poor metabolizer; SBP, systolic blood pressure; SD, standard deviation.
Hardy-Weinberg equilibrium χ 2 = 0.85 (P > 0.05). *4 Allele frequency = 0.22.
mg (P = 0.04), respectively. Thus, to achieve a one-beat reduction in HR during titration, the average EM patient required 7.7 mg of metoprolol, as compared with 5.9 mg in the IM patient and 5.3 mg in the PM patient. A significant difference was also seen in HR reduction when individuals first received their maximum-tolerated metoprolol dose (EM, IM, and PM: 21.4, 24.8, and 28.3 beats per min, respectively; P = 0.04; Table 3 ). The occurrence of HR ≤60 beats per min differed between genotypic groups. The odds ratio (OR) for achieving HR ≤60 beats per min, as compared with the EM group, was 1.72 (95% CI: 1.07-2.76; P = 0.02) in the IM group and 2.33 (95% CI: 0.71-7.61; P = 0.27) in the PM group. This corresponds to 71 (37.6%) EMs, 57 (50.9%) IMs, and 7 (58.3%) PMs achieving a HR ≤60 beats per min at least once during dose titration or follow-up.
No significant differences were observed in systolic blood pressure reductions during follow-up (P = 0.17-0.90) or at maximum dose (P = 0.56). By contrast, significant decreases in DBP were observed during titration, e.g., at Week 4 (EM, IM, and PM: 3.2, 5.0, and 7.1 mm Hg, respectively; P = 0.03). Significant decreases were also observed in the DBP achieved at maximum-tolerated metoprolol dose (11.4, 13.3, and 16.6 mm Hg, respectively; P = 0.02; Table 3 ).
Effect of CYP2D6 genotype on discontinuation and clinical outcome
The risk of permanent early discontinuation of controlled/ extended-release (CR/XL) metoprolol, as compared with the same for placebo, was low and similar in all groups (EMs: OR = 0.55, 95% CI = 0.25-1.19, P = 0.12; IMs: OR: 0.96, 95% CI: 0.49-1.91; P = 0.92; and PMs: OR: 0.59, 95% CI: 0.05-7.43; P = 0.81). There was no difference in distribution of *1 or *4 alleles, or CYP2D6 genotype, between the event/nonevent groups in the metoprolol-or placebo-treated subpopulations. Genotype conferred no effect on all-cause mortality and hospitalization in this substudy population-combined end points were similar in the EM (OR: 0.62; 95% CI: 0.37-1.06, P = 0.08), IM (OR: 0.71; 95% CI: 0.36-1.45, P = 0.36), and PM (OR: 0.80; 95% CI: 0.11-5.77, P = 0.83) groups. Overall, this substudy demonstrated the significant benefit of metoprolol CR/XL therapy (OR: 0.63; 95% CI: 0.43-0.94, P = 0.02).
DISCUSSION
This study is the first to evaluate the allele dose-response association of CYP2D6 genotype with steady-state metoprolol pharmacokinetics, pharmacodynamics, therapeutic efficacy, and clinical outcome in an HF cohort. These data demonstrate that the common, nonfunctional *4 allele of the CYP2D6 gene modulates metoprolol CR/XL pharmacokinetics and pharmacodynamics during dose titration. In the context of this MERIT-HF substudy, with limited sample size and variability in pharmacodynamic responses, patients were observed to tolerate and benefit equally from metoprolol therapy, regardless of CYP2D6 genotype.
Pharmacokinetic and pharmacodynamic effects
We observed a significant CYP2D6 allele/S-metoprolol doseresponse effect; median plasma concentrations were 4.6-fold greater in PMs and 2. Table S1 online) [26] [27] [28] [29] [30] [31] and the aforementioned meta-analysis. 32 Interestingly, in the current study, these differences attenuated at greater doses (≥130 mg/day), becoming nonsignificant at 3 months. This represents a novel finding, potentially due to the saturation of β-blockade, and supports the hypothesis made by Rau et al. that it is not possible to "simply extrapolate … findings to higher doses of metoprolol, because the extent of β-blockade may plateau at higher doses, with a subsequent mitigation of the differences between PMs and non-PMs. " 31 It remains unclear why there is a significant DBP reduction in PMs, but this finding cannot be attributed to confounding by antihypertensive polypharmacy and is robustly replicated by other studies. 29, 30 In a previous case-control study of metoprolol-treated hypertensive patients, PMs were fivefold (4.9-5.2) more prevalent among those experiencing adverse effects (P < 0.0001). 27 However, in subsequent prospective studies, CYP2D6-mediated pharmacokinetic differences did not translate into differential efficacies or dose-limiting adverse event rates. 26, 28, 29, 38, 39, 40 Only one study has evaluated CYP2D6 genotype in the context of HF, determining no association with tolerability to metoprolol CR/ XL. 26 However, the study (n = 51) was inadequately powered to detect subtle differences in outcomes. In the current study, which had greater power, the prevalence of permanent early discontinuation, all-cause mortality, and hospitalization were equivalent in each genotypic subgroup.
Earlier studies of MERIT-HF
The current study may offer additional insight into the results of an earlier MERIT-HF analysis. 10 In this study, the entire metoprolol-treated MERIT-HF cohort was retrospectively divided; one group received ≥100 mg/day, and the other received <100 mg/day. HR reduction and overall clinical outcome were comparable in the two groups, suggesting similar β-blockade despite differences in dosage and indicating greater sensitivity for β-blockade in the low-dose group. We assessed whether CYP2D6 genotype may explain this observation. However, the numbers of IMs and PMs were similar in the two dosage groups (≥100 mg: 36.5% IMs and 3.5% PMs vs. <100 mg: 28.0% IMs and 8.0% PMs; P = 0.42), from which we conclude that CYP2D6 genotype is not responsible for this effect.
Limitations
This study is restricted by its retrospective character-the availability of plasma samples and follow-up data was limited by the design of the MERIT-HF trial. In the context of the limited sample size and expected pharmacodynamic variability of this clinical study, there is borderline power to detect infrequent or small magnitudes of pharmacodynamic and clinical effects. Indeed, this power reduction is imposed by the need for genotypic stratification, which subdivides the study Figure 3 The relationship between the achieved dose of controlled/extended-release (CR/XL) metoprolol and mean decrease in heart rate during the titration phase, up to the 12-week follow-up visit, stratified by CYP2D6 genotype subgroups. The dose of metoprolol at each follow-up visit (2, 4, 6, 8, and 12 weeks, w) did not differ significantly among the groups. At 8 weeks (day 56 of follow-up, by which time, patients should have been titrated to the final dose), the mean reductions in heart rate from baseline in the EM, IM, and PM groups were 0.13, 0.17, and 0.19 beats per min per mg (P = 0.04), respectively. By comparison, in the placebo treatment arm, heart rate after 3 months was reduced by 2.8 beats per min. 1 The table below the graph displays the 95% confidence intervals (CIs) for each heart rate reduction/dose point plotted. EM, extensive metabolizer; IM, intermediate metabolizer; PM, poor metabolizer. population. Thus, to evaluate the greatest effects of the rare, nonfunctional CYP2D6*4 allele on metoprolol metabolism, asymmetric comparisons between a small group (PM; n = 12) and much larger groups (IM, n = 112; and EM, n = 189) were necessitated. Genotyping the CYP2D6 locus is challenging; >80 polymorphic variants of the coding/promoter regions have been identified, including single-nucleotide polymorphisms, insertion/ deletions, repeats, and gene conversion mutations, many of which code for nonfunctional or reduced-function enzymatic products (Figure 1 ). In the current study, we determined the presence of the 1846G>A 2D6*4 single-nucleotide polymorphism, which predicts >75% of PM genotypes in Caucasian European populations. 25, 30 We did not discriminate between the *1 (default) genotype and the less-frequent nonfunctional/ partially functional variants (e.g., *3 and *5), which, as a result, may have led to the inclusion of some PMs in the IM and EM groups. Finally, we detected 4.5% PMs in this study, as compared with the expected 6-7% from previous population surveys. Importantly, these misclassifications would tend to make our 34 MERIT-HF was an international, multicenter, doubleblind, randomized, placebo-controlled trial (n = 3,991) of patients with chronic, symptomatic HF (New York Heart Association II-IV); a leftventricular ejection fraction ≤0.40; and treatment with optimal standard therapy. Patients were randomly assigned to once-daily CR/XL Metoprolol (AstraZeneca, London, UK) or matched placebo. 1 Patients coadministered CYP2D6 substrates/inhibitors or other β-adrenergic receptor antagonistic agents were excluded from the study. MERIT-HF was performed with a low initial dose (12.5 or 25 mg/day; 12.5 mg was recommended for New York Heart Association III-IV patients) and progressive, biweekly, upward titration to a maintenance dose target of 200 mg/day. Dose regimen could be modified according to the judgment of the investigator. If a patient did not tolerate increases in dose, a temporary decrease in study drug or increase in diuretic dose was recommended. Patients were asked to attend follow-up visits every 3 months. The MERIT-HF International Steering Committee prematurely stopped the study after a mean follow-up period of 339 days (range: 200-555 days)-when the predefined criteria for stopping the study-were achieved. The metoprolol treatment arm demonstrated significant allcause mortality reduction (34%; 7.2% vs. 11% per patient-year).
Determination of CYP2D6 genotype. We examined the most common nonfunctional CYP2D6 polymorphism, CYP2D6*4. Genomic DNA was extracted successfully from a frozen (−20 °C) venous blood sample collected from 621 patients at the 90-day follow-up visit. Genotyping was not determined in the remaining 97 patients (venesection never performed, n = 72; death before venesection, n = 12; suboptimal quality of long-term stored DNA, n = 13). The yield and the purity of genomic DNA samples were determined by spectrophotometry (NanoDrop ND-1000; Thermo Scientific, Waltham, MA), and samples were diluted to 10 ng/µl. Genotyping of the nonfunctional CYP2D6*4 (1846G>A; rs3892097) polymorphism using a TaqMan validated single-nucleotide-polymorphism assay (ID: C__27102431_D0) was performed in accordance with the manufacturer's protocol, using a 7900HT real-time PCR sequence detection system (SDS; Applied Biosystems, Foster City, CA). Realtime PCR reactions were performed in a total volume of 5 μl, consisting of Genotyping Master Mix (2.5 μl), assay-specific TaqMan probe and primers (0.125 μl), double-distilled water (0.375 μl), and genomic DNA (20 ng; 2 μl). The thermal profile used to amplify the DNA consisted of an initial denaturation step (95 °C: 10 min), followed by 50 cycles of denaturation (95 °C: 15 s), annealing and combined extension (60 °C: 1 min). Genotypes were ascertained using the allelic discrimination function of the SDS 2.2 software package, via measurement of allele-specific fluorescence, providing semiautomated assignment with ≥95% confidence. Genotypes were validated using a PCR-linked restriction fragment length polymorphism typing assay that has previously been described in detail. 41, 42 The combined real-time PCR and PCR-restriction fragment length polymorphism genotyping success rate was >99.0%.
Subjects homozygous for the nonfunctional CYP2D6*4 allele were classified as PMs (*4/*4), and those heterozygous for the nonfunctional CYP2D6*4 allele were classified as IMs (*1/*4). In the absence of the nonfunctional *4 allele, individuals were classified as wild-type EMs (*1/*1).
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
3 Previous studies of low-dose metoprolol CR/XLtreated hypertensive patients have robustly established CYP2D6 genotype as a determinant of metoprolol CR/ XL pharmacokinetics without confirming definite differences in pharmacodynamic response.
WHAT QUESTION DID THIS STUDY ADDRESS?
3 This study evaluated the effect of CYP2D6 genotype on metoprolol pharmacokinetics, pharmacodynamics, and clinical outcome in a large subgroup of the MERIT-HF study.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
3 This study definitively confirms the allele-dose pharmacokinetic relationship between genotype and steady-state plasma metoprolol concentration and indicates that PMs of metoprolol experience greater heart rate reductions during dose titration as compared with EMs. However, CYP2D6 genotype did not adversely affect metoprolol treatment efficacy in the context of the limited sample size and the expected pharmacodynamic variability of this study.
HOW THIS MIGHT CHANGE CLINICAL PHARMACOLOGY AND THERAPEUTICS
3 Stratified approaches to the prescription and dose titration of cardiovascular drugs, such as β-blockers, based on pharmacogenetic factors such as CYP genotype may offer the optimization of pharmacotherapy in heart failure.
